In the first eight months of 1996, Belarus imported pharmaceuticals worth $50 million from 18 countries and 52 foreign drug manufacturers, according to the Minsk Economic News. The major part of the imports, 31% of the total, came from the USA, followed by 10% from Germany, 9% from Poland and 6% from Switzerland. These drugs have been purchased on credit. The total Belarusian drugs market is estimated to be worth $260 million a year.
Anatoli Gareev, director general of the Farmatsia drugs producer, said the Belarusian pharmaceutical market is characterized by the availability of a large selection of drugs, but that these drugs have a slow turnover. In addition, there is a highly seasonal nature to drug sales, and 80% of available drugs on the market are imported, he said.
Market Undermined By Poor Economy Generally, the stability of the pharmaceutical market is being undermined by the difficult economic conditions in the manufacturing sector as a whole. The very low purchasing power of consumers is also restricting sales of drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze